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 Abstract 
 
Biocatalysis using flavoprotein monooxygenases is coming of age, with intense research and 
development being carried out within the last decade. The reason behind their popularity is the 
vast array of reactions which they can catalyze including Baeyer-Villiger oxidation, 
sulfoxidation and epoxidation reactions. Members of Class B flavoprotein monooxygenases, 
especially Baeyer-Villiger enzymes, are highly selective in their chemo-, regio-, and 
enantioselective oxygenation reactions and are useful in the synthesis of high-value chemicals. 
Their catalysis products have wide applications in various fields including chemical, cosmetic 
as well as pharmaceutical industries. Moreover, in the era of a drive for more environmentally-
friendly reactions with the use of less toxic reagents and ambient temperatures, these 
flavoproteins are well-suited to the principles of green chemistry. 
This mini review provides an overview of some stereoselective reactions carried out by Class 
B flavoprotein monooxygenases and the efforts made in order to make these biocatalysts 
suitable for industrial applications. 
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1.   INTRODUCTION 
 
Flavoprotein monooxygenases are a large class of enzymes that are responsible for the 
activation and utilization of molecular oxygen for the monooxygenation of a many different 
compounds including drugs, pesticides and other xenobiotics.  During their catalytic cycle, one 
atom of molecular oxygen is incorporated into their substrate, while the other is reduced to 
water. The key step in their catalytic cycle is the formation of a flavin intermediate, C4a-oxygen 
adduct (Massey, 1994). Only the reduced flavin can react and activate molecular oxygen. The 
monooxygenase systems are typically reduced by a physiological electron partner, either 
NADPH or NADH, that donates the electrons required for catalysis. Since the electron source 
is not the substrate itself, they are called “external monooxygenases”. It is believed that the 
reduced flavin upon binding oxygen, generates a radical pair between the one electron reduced 
flavin and the superoxide radical (Massey, 1994). The latter radical pair gives rise to the C4a-
(hydro)peroxyflavin intermediate, that can oxygenate the substrate. The C4a-(hydro)peroxy 
intermediate of each monooxygenase system can decay with a different velocity, whilst a 
nucleophilic or electrophilic attack on the substrate will take place depending on the 
protonation state of the flavin. Several crystal structures of flavoprotein monooxygenases are 
now available (Malito et al., 2004; Eswaramoorthy et al., 2006; Alfieri et al., 2008; Mirza et 
al., 2009) and they can be used together with sequence alignment to predict and understand 
folding determinants that are responsible for carrying out monooxygenation reactions (Gao et 
al., 2016). Furthermore, these crystal structures also show the relatively large and accessible 
active sites of these proteins which could be one reason for their promiscuity (Figure 1). 
 
2.   CLASSIFICATION 
Flavoprotein monooxygenases can be classified using different parameters such as the reaction 
that they catalyze, the type of substrates they can accommodate and/or their conserved 
structural elements. However, in many cases the crystal structure of the members of this vast 
group of enzymes is not available, so the classification is mainly based on sequence homology 
rather than structural data. Van Berkel and colleagues (Van Berkel et al., 2006) proposed six 
different groups (A-F) based on structural and functional properties of flavin-dependent 
monooxygenases.  
Class A monooxygenases are encoded by a single gene, contain a tightly bound FAD cofactor, 
can work with NADPH or NADH, they release NADP+ immediately upon flavin reduction, 
they contain one nucleotide binding domain for FAD. The C4-hydroperoxyflavin performs 
electrophilic attack on the aromatic ring of an activated compound containing an activated 
nitrogen or hydroxyl group (Moonen et al., 2002).  
Class B monooxygenases are also encoded by a single gene, contain a tightly bound FAD 
cofactor, depend on NADPH as coenzyme, keep the NADP+ bound during catalysis and are 
composed of two dinucleotide binding domains (for FAD and NADPH). Enzymes belonging 
to this class can catalyze carbon, nitrogen, sulfur or phosphorous oxidation. Three subfamilies 
can be identified within this class on the basis of their sequence features (Fraaije et al., 2002): 
flavin-containing monooxygenases (FMOs), microbial N-hydroxylating monooxygenases 
(NMOs) and Baeyer-Villiger monooxygenases (Type I BVMO). 
Unlike class A and B, Class C monooxygenases are encoded by multiple genes encoding for 
one or two monooxygenase components and a reductase component, use FMN as coenzyme 
and can use NADPH or NADH (Fischer et al., 1995). Bacterial luciferases and Type II BVMOs 
are the most studied examples of enzymes that belong to this class.  
Classes D-F are encoded by two genes, a monooxygenase and a reductase, use FAD as a 
coenzyme and can use either NADPH or NADH as their electron donor.  
In this mini review we will focus mainly on the description of two subfamilies that belong to 
Class B: Baeyer-Villiger monooxygenases (BVMO) and flavin-containing monooxygenases 
(FMO). 
 
3.   BVMO 
The chemical Baeyer-Villiger reaction was discovered in 1899 by Adolf von Baeyer and Victor 
Villiger (Baeyer and Villiger, 1899). In this oxidation mechanism a ketone compound is 
attacked by a nucleophilic peroxy acid to form a tetrahedral intermediate called “Criegee 
intermediate”. This species is unstable and undergoes a rearrangement through an expulsion of 
a carboxylate ion and a migration of a carbon-carbon bond, resulting in an ester or lactone 
being formed and a carboxylic acid side product (Ballou and Entsch, 2013). The obvious 
disadvantages of the chemical reaction are both the need for a peracid as reagent and the 
equimolar production of an undesired carboxylic acid. These chemical oxidants utilized as 
reagents are not only expensive, but tend to be unstable and even explosive, presenting a safety 
risk. Moreover, the side product of the reaction (a carboxylic acid that depends on the organic 
peracid used as oxidant) must be recycled or disposed.   
Baeyer-Villiger monooxygenases (BVMOs) catalyze specific Baeyer-Villiger oxidations on 
the carbonyl moiety of substrates with high regio- and enantioselectivity. In addition, they can 
also catalyze the electrophilic heteroatom oxygenation including nitrogen and sulfur (Walsh 
and Chen, 1988). These proteins have a great value in the conversion of ketones into the 
corresponding esters and lactones, bioremediation purposes and green chemistry applications 
such as the synthesis of chiral intermediates. Unlike the chemically driven B-V reaction, the 
BVMOs carryout their catalysis without the use of strong chemical oxidants and without 
formation of side products, but more importantly as mentioned above, in a highly regio- and 
enantioselective manner.  
BVMO enzymes are abundant in bacterial, fungal and plant genomes but nearly absent in 
animal or human genomes. They are involved in metabolic pathways (Chen et al., 1988; Sheng 
et al., 2001; Minerdi et al., 2015) and in some cases have medical relevance (Fraaije et al., 
2004; Minerdi et al., 2012; Catucci et al., 2016; Minerdi et al., 2016). The first BVMO enzyme 
that was isolated and purified was a cyclohexanone monooxygenase (CHMO) from 
Acinetobacter NCIMB 9871 (Donoghue et al., 1975). Since the late 90s many other BVMO 
enzymes have been cloned and characterized in terms of catalytic activity towards a broad 
range of compounds. A huge leap forward in the understanding of these enzymes was 
subsequently achieved with the publication of the first crystal structure of a type 1 BVMO, 
Phenylacetone monooxygenase (PAMO) (Malito et al., 2004).  
All BVMO enzymes characterized to date catalyze a monooxygenation incorporating one atom 
of molecular oxygen into the substrate and reducing the other to water (Figure 2). The catalytic 
mechanism is similar to those previously described in literature for other flavin-containing 
enzymes with the addition of the Criegee intermediate.  
 
3.1.   BIOCALAYSIS by BVMOs 
BVMOs present various catalytic activities and a wide substrate range, making them perfect as 
biocatalysts for large-scale synthetic applications as well as biotechnological applications. The 
first BVMO to be studied in detail was cyclohexanone monooxygenase (CHMO) from 
Acinetobacter sp. (NCIMB 9871) which converts a cyclic ketone to a lactone, which can 
subsequently be hydrolyzed to an aliphatic acid. Under physiological conditions, CHMO 
catalyzes a key step in the biodegradation of cyclohexanol (Sheng et al., 2001). These enzymes 
are present in different bacterial genomes and have been studied in depth for many years. 
Acinetobacter calcoaceticus NCIB 9871 is a bacterial strain also capable of growing on 
cyclohexanol as its sole carbon source (Donoghue et al., 1975). The metabolic pathway for the 
degradation of the alcohol involves the CHMO in the second step of the oxidation. Adipic acid, 
as a final product of this metabolism, is then further oxidized during β-oxidation to form acetyl-
CoA and Succynil-CoA. This pathway can be exploited both for the synthesis of ε-caprolactone 
and adipic acid. In the former case, the CHMO product can be used to produce 
polycaprolactone via ring opening polymerization (Labet et al., 2009). Polycaprolactone (PCL) 
is a polyester with interesting physical and chemical properties and, more importantly, it is also 
biodegradable. Whereas, in the latter case, industrial production of adipic acid could be applied 
to Nylon 6,6 synthesis (Leisch et al., 2011). Nylon 6,6 is a polymer obtained from the 
condensation of adipic acid and hexamethylenediamine to form a 12 carbons repeating unit. 
Currently the synthesis of these compounds is still performed chemically (Raja et al., 2006) 
but in the near future biocatalysis could be an interesting alternative to this approach.   
CHMO from Acinetobacter calcoaceticus NCIMB is another well-studied of these CHMO 
enzymes. In 1988 Stewart published a paper in which he used this CHMO for the synthesis of 
(bicyclic) lactones (Stewart, 1988). Colonna and co-workers in 1996 showed that the same 
CHMO has a wide substrate selectivity towards organic sulfur compounds. They were 
interested in synthesis of various sulfoxides not only due to their involvement in many 
biological activities but also for their pharmaceutical importance. They demonstrated that this 
enzyme was able to oxidize alkyl aryl sulfides, disulfides, dialkyl sulfides, cyclic and acyclic 
1,3-di- thioacetals and 1,3-oxathioacetals to the corresponding mono-sulfoxides, with high 
e.e.s (Colonna et al., 1996). A couple of years later, the same research group showed that 
CHMO was also able to oxidize organic cyclic sulfites to their corresponding sulfates (Colonna 
et al., 1998). Cyclic sulfites and sulfates are considered to be the synthetic equivalents of 
epoxides, capable of reacting with a large variety of nucleophiles.  
To date, more than hundred different substrates for CHMO have been identified and the reader 
is referred to a detailed review by Mihovilovic’s group (Mihovilovic et al., 2002). 
Another interesting BVMO, this time active on aromatic compounds, is 4-
hydroxyacetophenone monooxygenase (HAPMO) which was isolated from Pseudomonas 
fluorescens ACB (Higson and Focht, 1990). Substrate specificity of this enzyme covers 
different ketones including aryl ketones. Conversion of ring-substituted aryl ketones into 
phenyl acetates by HAPMO provides an alternative route for synthesis of precursors of 
pharmaceutically important compounds (Held et al., 1999). Fraaije’s group have published a 
review including the many different reactions catalyzed by HAPMO (Kamerbeek et al., 2003). 
BVMOs have another interesting characteristic that can be exploited for organic synthesis. 
These enzymes perform highly regio- and enantio- selective reactions on both ketone and soft 
nucleophilic substrates. In the chemical Baeyer-Villiger oxidation the oxygen insertion occurs 
only within the carbonyl carbon and the most substituted adjacent carbon of the substrate 
whereas, interestingly, BVMOs show regiodivergency on some substrates. This means that 
according to the enantiomeric properties of the substrate, different regioisomers of the product 
can be obtained. An interesting example is the regiodivergent conversion of 
(±)Bicyclo[3.2.0]hept-2-en-6-one in the two corresponding regioisomer products: (-)-(1S, 5R)-
2-oxabicyclo[3.3.0]oct-6-en-3-one and (-)-(1R, 5S)-3oxabicyclo[3.3.0]oct-6-en-2-one. This 
reaction is also highly enantioselective yielding nearly 1:1 ratio of the regio-isomer products 
with high enantiomeric purity (Hilker et al., 2008). This “unexpected” lactone can be used as 
precursor for the synthesis of several brown algae pheromones such as multifidene and viridene 
(Lebreton et al., 1997).   
Another BVMO, cyclopentadecanone monooxygenase (CPDMO) from Pseudomonas sp. 
strain HI- 70, was shown to prefer cyclic and bicyclic ketones with 7–16 carbons atoms (Iwaki 
et al., 2006). When tested with 33 ketosteroids, another group (Beneventi et al., 2009) showed 
that CPDMO in not only able to accommodate in its active site flexible rings such as 
cyclopentadecanone, but also more structurally demanding compounds such as steroids. The 
enzyme was able to catalyze the B-V oxidation of 3-keto and 17-ketosteroids with full control 
of the regiochemistry of the produced lactones (Beneventi et al., 2009). Steroids are a highly 
sought after class of natural products with a multitude of pharmacological properties.  
BVMOs are often reported in literature as performing the resolution of racemic mixture of 
substrates. An interesting study on both PAMO and HAPMO reports this catalytic activity 
towards several substituted benzylketones (Rodriguez et al., 2009). Both PAMO and HAPMO 
can perform highly enantio-selective resolutions of racemic ketones presenting a good method 
for the preparation of both enantiomerically pure benzyl ketones and esters.  
Finally, some of the different reactions carried out by Class I BVMO enzymes are summarized 
in Table 1. 
 
3.2.   INDUSTRIAL APPLICATION 
Nowadays enzyme cloning, expression and purification has become routine and there are many 
variety of ways to produce the BVMO biocatalysts that can be exploited for the generation of 
the desired chemical product. However, the main bottleneck in using BVMOs in large scale 
chemical production, is their dependence on stoichiometric amounts of the reduced 
nicotinamide coenzyme NADPH (Torres Pazmino et al., 2010) and its high cost. There are 
several solutions to overcome this problem, some of which are based on the recycling of the 
oxidized cofactor that is the by-product of the enzymatic reaction. In order to do so, one needs 
to find a way to catalyze the reverse reaction yielding the reduced form of NAD(P) that is 
needed for the reaction of interest. The approach can either be chemical, electrochemical, 
photochemical or enzymatic.  
 
3.2.a COFACTOR RECYCLING 
In the chemical approach, regeneration of the nicotinamide coenzyme can be performed by 
exploiting rhodium complex [Cp*Rh(bpy)(H2O)]2+ (Hollmann et al., 2002). The use of this 
compound leads to the formation of CO2 which can be easily removed from the reaction. 
Unfortunately, this chemical reaction occurs under alkaline conditions and it is hardly 
compatible with many enzymatic reactions (Hollmann and Schmid, 2004).  
Another tested method is electrochemistry. The main advantage of using electrochemistry for 
cofactor regeneration is due to the low cost and the ease of separation of the products. The 
regeneration can be a direct reduction occurring at the cathode electrode (Hollmann et al., 2001; 
Kim and Yoo, 2009). The use of mediator can be exploited for indirect reduction of the 
coenzymes (Sadeghi et al., 1997; Hollmann et al., 2001). The mediator can also be a protein 
that shuttles the electrons from the cathode to the cofactor selectively (ferrodoxin NADP+ 
reductase, NAD(P)+ dehydrogenases). Immobilization techniques on the electrode surface are 
also available and can be used for cofactor regeneration or bypassing the need for NADPH 
(Castrignano’ et al., 2010; Sadeghi et al., 2010; Castrignano’ et al., 2012; Castrignano’ et al., 
2015).  
Another attractive method is the photochemical approach where solar light can be used to 
reduce light-sensitive material that can be exploited for the electron transfer following the 
absorption of light. Examples of these light-sensitive materials include [Ru(bpy)3]2+, Zn-
TMPyP4+, flavin dyes, Fe2O3 and TiO2 that are able to generate electrons from electron donors 
such as EDTA. The reduction occurs through an electron carrier, like methyl viologen, that is 
able to transfer the electrons to NAD(P)+-dependent enzymes. This approach was successfully 
demonstrated by Reetz’s group showing the BVMO oxidation of prochiral ketones (Hollmann 
et al., 2007). However, the poor efficiency of this system needs to be addressed. 
The enzymatic regeneration of the nicotinamide cofactor seems to be the method of choice 
with more publications than any other regeneration system. The coenzyme regeneration 
systems are based on a coupled enzymatic reaction that produces NADPH at the expense of 
another substrate. The sacrificial substrate is an important point to consider as it can influence 
the cost of the reaction. Typical coupled enzymes include glucose-6-phosphate dehydrogenase, 
alcohol dehydrogenase and glucose dehydrogenase. A more recent alternative has been the 
production of fusions using protein engineering between these enzymes and BVMOs in order 
to produce a self-sufficient BVMO (Torres Pazmino et al., 2009; Ceccoli et al., 2014). 
 
3.2.b WHOLE CELL 
A more comprehensive approach that allows both desired product formation and cofactor 
regeneration is the use of whole cell systems since the host cell provides the NADPH. In this 
type of set up the biocatalyst is expressed by the host cell either by genetic engineering of the 
host, typically E. coli or yeast, or transforming the host with a plasmid containing the coding 
sequence of the desired target enzyme. The clone expansion into a suitable media for growth 
via fermentation will result in the production of microbial cells containing the desired catalysts 
ready to perform the enzymatic reaction. During the fermentation the microbial cells are 
supplemented with the substrate of interested that is converted by the enzyme. At the end of 
the process the product is extracted using an organic solvent separation methodology.  
There are a number of examples of successful whole-cell catalysis using the BVMO enzymes. 
In 2005, Rial et al. used the whole-cell approach to perform a screening on the transformation 
capabilities of Xanthobacter sp. ZL5. In their work Rial and colleagues performed a substrate 
profiling using a collection of mono-substituted cyclic ketones, fused bicyclobutanones and 
terpenone derivatives (Rial et al., 2008). Dudek and colleagues in 2013 developed a generic 
whole based method for BVMOs (Dudek et al., 2013). The latter research group used the 
PAMO from Thermobifida Fusca and decided to direct the functional protein to the periplasm, 
so that the substrate could always be available to the enzyme and to enhance the exchange of 
the cofactor with the phosphite dehydrogenase (PTDH) which was the cofactor regenerator. 
Interestingly the byproduct of PTDH, phosphate, can also be used to assess BVMO assay 
(Dudek et al., 2013). The molybdate assay, through colorimetric detection, was employed to 
quantify phosphate.  
More recently Summers and co-workers identified a BVMO in R. jostii that catalyzed the 
regioselective biotransformation of bicyclo[3.2.0]hept2-en-6-one to the corresponding lactone. 
Also in this case the enzyme, named MO14, was tested in a whole-cell fermentation system 
investigating the biotransformations on a gram scale (Summers et al., 2015).  The whole-cell 
system offers economical advantages over purified enzymes, but also poses more problems in 
terms of reproducibility of the results and production of unwanted byproducts. Moreover, the 
substrate cannot always enter the cell membrane and the product once formed could also be 
degraded due to the metabolism of the host.  
Pure enzyme-based catalysis remains a valuable way to produce high added value products and 
whole-cell systems can overcome some of the economical barriers that prevent some enzymes 
and specifically monooxygenase systems from being industrially exploited.  
 
4.   Flavin-containing monooxygenases (FMOs) 
Apart from class I BVMOs, another group of enzymes called flavin-containing 
monooxygenases (FMOs) are also part of Class B flavin-dependent monooxygenases (Van 
Berkel et al., 2006). Unlike BVMOs, the FMOs are also present in animals and humans. The 
mammalian FMOs comprise a family of five functional enzymes (FMO 1-5) and are 
membrane-bound, generally making them more difficult for use in biocatalysis. However, a 
more soluble version of the human FMO3 enzyme has been reported by the truncation of the 
membrane-anchor (Catucci et al., 2012).  In general, the FMO enzymes catalyze the 
oxygenation of a wide variety of nucleophilic heteroatom-containing compounds, mainly 
sulfur and nitrogen (Figure 3). The mammalian FMOs are classified as drug metabolizing 
enzymes and show overlapping substrate spectra with cytochromes P450. 
The FMO-catalyzed oxygenation reaction can be divided into two sequential reactions, the 
reductive and oxidative half-reactions. In the reductive half-reaction, the FAD cofactor is first 
reduced to FADH2 by NADPH and subsequently reacts with molecular oxygen to yield the 
C4a-(hydro)perooxyFAD intermediate. During the oxidative half-reaction and in the presence 
of substrate, an oxygen atom is transferred from the intermediate to a substrate to generate an 
oxygenated product and H2O. Structures of protein-cofactor and protein-substrate complexes 
for a eukaryotic FMO (yFMO) from Schizosaccharomyces pombe (Eswaramoorthy et al., 
2006) and a prokaryotic FMO (mFMO) from Methylophaga sp. Strain SK1 (Alfieri et al., 2008) 
provide insights into their possible mechanisms of action. 
The best studied bacterial FMO, mFMO, is active against N- and S-containing compounds such 
as trimethylamine and thiourea but its notable reaction is its ability to produce indigo blue 
(Choi et al., 2003). More recently, a fusion of this enzyme and PTDH has been reported (Rioz-
Martinez et al., 2011). PTDH-mFMO was tested by these authors for enantioselective oxidation 
of thioanisole derivatives, with the most effective conversion yielding 95% of (S)-methyl 
phenyl sulfoxide. The fusion enzyme was also shown to oxidize methyl p-tolyl sulfide and p-
chlorophenyl methyl sulfide into the corresponding sulfoxides with high enantiomeric excesses 
i.e. more than 90%. These authors also successfully demonstrated the oxidization of indole and 
analogues into the corresponding indigoid pigments by PTDH-mFMO (Rioz-Martinez et al., 
2011). The latter pigments are interesting dyes and bioactive compounds. In 2012, work on a 
first marine bacterial FMO was published (Jensen et al., 2012) which was shown to catalyze 
both B-V oxidations of carbonyl compounds as well as sulfoxidation of prochiral sulfides. An 
example of the latter sulfoxidation reaction was demonstrated by obtaining (R)-4-chlorophenyl 
methyl sulfoxide with an optical purity of > 80%. 
Moving on from the bacterial to animal FMOs, the applications of especially mammalian 
FMOs in chiral separations are hampered and little-studied due to their typically membrane-
associated and thermal instability. However, some researchers have demonstrated the 
involvement of these mammalian enzymes in specific chiral reactions. For example, the 
purified rabbit lung FMO2 has been shown to be remarkably stereoselective for the 
sulfoxidation of methyl p-tolyl sulfide with an enantiomeric excess of 96% for the (R)-methyl 
p-tolyl sulfoxide (Rettie et al., 1994). Another example is that of Sulindac, a nonsteroidal anti-
inflammatory drug that contains a chiral sulfoxide moiety and is clinically administered as a 
racemic mixture. Sulindac sulfoxide is reduced in vivo to sulindac sulfide (Figure 4), the 
pharmacologically active metabolite (Hamman et al., 2000). In serum and urine of dosed 
volunteers, a distinct stereoselective enrichment of the (R)-sulindac sulfoxide is observed. 
Hamman and coworkers showed that purified mini pig liver FMO1, rabbit lung FMO2, and 
human cDNA expressed FMO3, all efficiently oxidized sulindac sulfide with a high degree of 
stereoselectivity towards the R-isomer (Hamman et al., 2000). In case of the human liver 
microsomes, FMO3, the (R)-sulindac sulfoxide was obtained with an e.e. of 87%. FMO1 and 
FMO2 were even more stereoselective in the formation of (R)-sulindac sulfoxide, with an e.e. 
of 98 and 99%, respectively (Hamman et al., 2000). These data are summarized in Table 2. 
In other examples, albendazole and fenbendazole sulfoxides, benzimidazole derivatives with 
anthelmintic activity were obtained using liver microsomes from sheep and cattle (Virkel et 
al., 2004). The authors showed that the sulfoxidation of albendazole led to the enantiopure 
sulfoxide. Another research group (Furnes and Schlenk, 2004) demonstrated how their FMO1 
mutants could oxidize the insecticide fenthion with excellent selectivity for the (+)-sulfoxide. 
 
Potential application of human FMOs 
In course of drug development process, drug metabolites are required for structure elucidation 
as well as standards used in analytical separations. Chemical synthesis of these drug 
metabolites requires multiple reaction steps including the protection and deprotection steps of 
some functional groups. However, this process can also be carried out by heterologously 
expressed and purified human FMOs in a single catalytic step in vitro (Catucci et al., 2013). 
As mentioned previously for the BVMO enzymes, whole-cell biocatalysis where time and costs 
of enzyme purification as well as cofactor recycling are obviated, can also be applied to the 
FMO enzymes. To this end, a recent study using human FMO3 in a whole-cell set up was 
reported for the synthesis of a high-priced human drug metabolite, moclobemide-N-oxide, on 
the multi-milligram scale (Halon et al., 2012). This study not only demonstrated the feasibility 
of using FMOs in a whole-cell set up but also opened the way for future applicability of these 
human biocatalysts in oxidation of drug candidates during the drug development process.  
 
Concluding Remarks 
Finally, in the last decade a huge effort has been made by different research groups as well as 
chemical companies to translate the many catalytic reactions of BVMO enzymes into large 
scale preparative conversions. To this end, CHMO and closely related BVMOs were used for 
the production of enantiopure products, mainly for application in the fragrance industry (Fink 
et al., 2013). In 2006 a company filed a patent for a process for the preparation of modafinil, a 
wakefulness-promoting drug used in the treatment of shift work sleep disorders (Riva et al., 
2006) using PAMO. This enzyme is able to convert the sulfide precursor to the correct 
enantiomer of this sulfoxide. More recently, another company has filed a patent for the 
production of the proton pump inhibitor esomeprazole by CHMO (Bong et al., 2013). The 
company used this enzyme to improve methods to manufacture chiral sulfoxides, which are 
important molecules for pharmaceutical synthesis. Their biocatalytic processes using BVMOs, 
improves enantiometric purity and reduces sulfone impurities. 
Given the importance of optically active lactones and sulfoxides in chemistry and medicine, 
together with the drive for less hazardous and more environmentally friendly reactions, the 
future looks very promising for flavoprotein monooxygenases. Although huge progress has 
been made for the use of these enzymes in large scale chemical syntheses, further improvement 
in the creation of stable and more selective monooxygenases is required in order for 
biocatalysis to win over pure chemical synthsis. 
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Table 1: Examples of stereoselective reactions catalyzed by BVMO enzymes. 
 
Enzyme   Substrate   Yield(%)   %R   %S   REFERENCE  
CHMO  
    
85   96   4   Berenzina  et  al.,  2002  
PAMO  
    
84   82   18   Gutierez  et  al.,  2005  
HAPMO  
    
84   14   86   Rodriguez  et  al.,  2010  
CPMO  
    
68   46   54   Iwaki  et  al.,  2002  
CHMO  
    
90   97   3   Colonna  et  al.,  2001  
CHMO  
    
n.r.   27   73   Light  et  al.,  1982  
PAMO  
    
94   44   56   De  Gonzalo  et  al.,  2006  
HAPMO  
    
55   15   85   De  Gonzalo  et  al.,  2006  
  
Table 2: Stereoselective sulfoxidations catalyzed by mammalian FMO enzymes. 
 
Enzyme   Substrate   product   ee  
cDNA-­expressed  
rabbit  FMO1  
  
  
>  99%  
cDNA-­expressed  
rabbit  FMO2  
  
  
>  99%  
Rabbit  liver  
microsomes  
  
  
96%  
Mini-­pig  liver  
FMO1  
  
  
98%  
Rabbit  lung  
FMO2  
  
  
99%  
cDNA-­expressed  
human  liver  
FMO3  
  
  
87%  
(a)   Rettie  et  al.,  1994  
(b)   Hamman  et  al.,  2000   
 
Figure 1 Access channel comparisons for flavoprotein monooxygenases. A, bacterial FMO 
from Methylophaga, volume 2981 Å3 (Protein Data Bank Code 2VQ7, Alfieri et al., 2008); B, 
yeast FMO from S. pombe, volume 2330 Å 3 (Protein Data Bank Code 2GV8, Eswaramoorthy 
et al., 2006); C, bacterial PAMO from Thermobifida fusca, 2367 Å 3 (Protein Data Bank Code 
1W4X, Malito et al., 2004); D bacterial CHMO from Rhodococcus, volume 1811 Å 3 (Protein 
Data Bank Code 3GWD, Mirza et al., 2009). Volumes were calculated using the CASTp 
program (Dundas et al., 2006). 
 
 
  
Figure 2 Scheme of the catalytic cycle of BVMO 
 
 
 
 
  
Figure 3 Selected substrates of FMO. Arrows indicate the positions of N- or S-oxygenation 
 
 
 
 
 
 
  
Figure 4 Biotransformation of sulindac. Racemic prodrug sulindac sulfoxide is reversibly 
reduced to the active sulfide metabolite, which is reoxidized by FMO to the (R)-sulfoxide 
enantiomer in high yields. 
 
 
 
 
